Hyponatremia and outcomes in patients with heart failure

Heart

Volumn 98, Issue 24, 2012, Pages 1761-1762

  Goldsmith, Steven R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; CONIVAPTAN; DEMECLOCYCLINE; LOOP DIURETIC AGENT; SODIUM; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ACUTE HEART FAILURE; DEATH; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SODIUM BLOOD LEVEL; SYSTOLIC HEART FAILURE; VASOCONSTRICTION; WATER DEPRIVATION;

ARGININE VASOPRESSIN; BENZAZEPINES; DISEASE PROGRESSION; HEART FAILURE; HUMANS; HYPONATREMIA; INCIDENCE; PROGNOSIS; RECEPTORS, VASOPRESSIN; SODIUM; SURVIVAL RATE; WORLD HEALTH;

EID: 84870475759     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302854     Document Type: Editorial

References (12)

1. Abraham WT, Fonarow GC, Albert NM, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2008;52:347-56.
2. Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006;119:71-8.
3. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005;46:1785-91.
4. Gheorghiade M, Shin DD, Thomas TO, et al. Congestion is an important diagnostic and therapeutic target in heart failure. Rev Cardiovasc Med 2006;7:12-24.
5. Lee ES, Choi DJ, Yoon CH, et al. Improvement of hyponatraemia during hospitalisation for acute heart failure is not associated with improvement of prognosis: an analysis from the Korean Heart Failure (KorHF) registry. Heart; 2012 (In press).
6. Gheorghiade M, Rossi JS, Cotts W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med 2007;167:1998-2005.
7. Klein L, O'connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005;111:2454-60.
8. Rossi J, Bayram M, Udelson JE, et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: Insights from the acute and chronic therapeutic impact of a vasopressin antagonist in chronic heart failure (ACTIV in CHF) trial. Acute Card Care 2007;9:82-6.
9. Madan VD, Novak E, Rich MW. Impact of change in serum sodium on mortality in patients hospitalized with heart failure and hyponatremia. Circ Heart Failure 2011;4:637-43.
10. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112.
11. Annane D, Decaux G, Smith N. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci 2009;337:28-36.
12. Gheorghiade M, Filippatos G, Pang PS. Changes in clinical, neurohormonal, electrolyte, renal and hepatic profiles during and after hospitaliation for acute decompensated heart failure: analysis from the EVEREST trial (late breaking clinical trial). Paper Presented at European Society of Cardiology; September 2, 2008, Munich, Germany.